X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddys Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  •
  • MyStocks
MEMBER'S LOGIN

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Dr. Reddys Quarterly Results   (REDY)

Here are the latest quarterly results of Dr. Reddys. For more details, see the Dr. Reddys financial fact sheet and Dr. Reddys share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

Dr. Reddys Quarterly Results

No. of Mths
Qtr. Ending		 3
Mar-17*		 3
Jun-17*		 3
Sep-17*		 3
Dec-17*		 3
Mar-18*		 3
Jun-18*		 3
Sep-18*		 3
Dec-18*		 8-Qtr Chart
Click to enlarge
Net Sales Rs m36,11933,33235,59838,34135,53937,36538,17538,646 
Other income Rs m2053803164304495041,2821,023 
Turnover Rs m36,32433,71235,91438,77135,98837,86939,45739,669 
Expenses Rs m30,21430,10028,90430,41429,90329,67730,58230,600 
Gross profit Rs m6,0073,3306,7867,9275,7057,7717,5938,046 
Depreciation Rs m2,5432,5922,7022,7152,7632,7872,7862,903 
Interest Rs m196215223172178195208241 
Profit before tax Rs m3,4739034,1775,4703,2135,2935,8815,925 
Tax Rs m972371,1232,5284925328071,011 
Profit after tax Rs m3,3766663,0542,9422,7214,7615,0744,914 
Gross profit margin %16.610.019.120.716.120.819.920.8 
Effective tax rate %2.826.226.946.215.310.113.717.1 
Net profit margin %9.32.08.67.77.712.713.312.7 
Diluted EPS Rs 20.4 4.0 18.4 17.8 16.4 28.7 30.6 29.7  
Diluted EPS (TTM) Rs 78.0 72.7 72.5 60.6 56.6 81.3 93.5 105.4  
 Subscriber Feature   View View View          
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: Dr. Reddys 3QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   PFIZER  NATCO PHARMA  FULFORD INDIA  CIPLA  ALEMBIC PHARMA  

Compare DR. REDDYS LAB With:   PFIZER  NATCO PHARMA  FULFORD INDIA  CIPLA  ALEMBIC PHARMA  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Where Will the Two-Faced Market Go from Here?(Podcast)

The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.

Views on news

SUN PHARMA Plunges by 5%; BSE HEALTHCARE Index Down 3.5% (Market Updates)

Feb 15, 2019 | Updated on Feb 15, 2019

SUN PHARMA share price has plunged by 5% and its current market price is Rs 441. The BSE HEALTHCARE is down by 3.5%. The top gainers in the BSE HEALTHCARE Index are CAPLIN POINT (up 1.5%) and DR. LAL PATHLABS LTD (up 1.3%). The top losers are SUN PHARMA (down 5.4%) and DR. REDDYS LAB (down 8.2%).

DIVIS LABORATORIES Plunges by 5%; BSE HEALTHCARE Index Down 3.3% (Market Updates)

Feb 15, 2019 | Updated on Feb 15, 2019

DIVIS LABORATORIES share price has plunged by 5% and its current market price is Rs 1,621. The BSE HEALTHCARE is down by 3.3%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 1.1%) and ERIS LIFESCIENCES LIMITED (up 1.0%). The top losers are DIVIS LABORATORIES (down 5.2%) and DR. REDDYS LAB (down 7.8%).

DR. REDDYS LAB Plunges by 20%; BSE HEALTHCARE Index Down 4.0% (Market Updates)

Feb 15, 2019 | Updated on Feb 15, 2019

DR. REDDYS LAB share price has plunged by 20% and its current market price is Rs 2,650. The BSE HEALTHCARE is down by 4.0%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 1.0%) and FORTIS HEALTHCARE (up 1.0%). The top losers is DR. REDDYS LAB (down 19.6%)..

DR. REDDYS LAB Plunges by 7%; BSE HEALTHCARE Index Down 2.9% (Market Updates)

Feb 15, 2019 | Updated on Feb 15, 2019

DR. REDDYS LAB share price has plunged by 7% and its current market price is Rs 2,650. The BSE HEALTHCARE is down by 2.9%. The top gainers in the BSE HEALTHCARE Index are DR. LAL PATHLABS LTD (up 1.2%) and FORTIS HEALTHCARE (up 0.9%). The top losers is DR. REDDYS LAB (down 7.4%)..

The BSE HEALTHCARE Index Down 3% ; DR. REDDYS LAB Among Top Losers (Market Updates)

Feb 15, 2019 | Updated on Feb 15, 2019

The BSE HEALTHCARE Index Down at 13,738 (down 3.1%). Among the top losers in the BSE HEALTHCARE Index today are DR. REDDYS LAB, GLENMARK PHARMA and DIVIS LABORATORIES. Meanwhile, the BSE Sensex has plunged 0.4% to 36,023.

More Views on News

Most Popular

7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

Feb 4, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

Here's What the Biggest 'Rebirth of India' Investors are Doing(The 5 Minute Wrapup)

Feb 5, 2019

A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Do You Have the Stomach to Survive a Small Cap Crash?(Profit Hunter)

Feb 5, 2019

While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Feb 15, 2019 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. REDDYS LAB

DR. REDDYS LAB - TORRENT PHARMA COMPARISON

Compare Company With Charts

COMPARE DR. REDDYS LAB WITH

OTHER USEFUL LINKS

MARKET STATS


ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
  • Get Equitymaster Android App on Google Play
  • Get Equitymaster iOS App on App Store
FOLLOW

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.